LEMAITRE VASCULAR INC (LMAT) Stock
LMAT has an Alpha Score of 49 out of 100 (weak), computed on Nov 5, 2026 from 3 of 4 sub-scores. 5 of the hedge funds AlphaScala tracks reported LMAT in 13F filings for the quarter ended Jun 30, 2026; the largest reported position is Renaissance Technologies's at $16.27M. Its trailing P/E ratio is 28.1 and its net margin 25.0% (key statistics as of Nov 5, 2026).
What is LMAT's Alpha Score?
How it works →Alpha Score of 49 reflects weak overall profile with moderate momentum, weak value, strong quality. Based on 3 of 4 signals – score is capped at 90 until remaining data ingests.
Computed from 3 of 4 sub-scores; a sub-score is left out when its inputs are missing, and the composite is capped accordingly.
Computed Nov 5, 2026
A rules-based research rating, not a recommendation to buy or sell.
Which hedge funds own LMAT?
From 13F filings| Fund | Shares Held | Position Value | Change vs prior Q |
|---|---|---|---|
| Renaissance Technologies Jim Simons (founder) | 170K | $16.27M | +22% |
| Citadel Ken Griffin | 43K | $4.11M | -56% |
| Marshall Wace | 37K | $3.59M | -72% |
| D.E. Shaw David Shaw | 36K | $3.50M | -56% |
| Millennium Management Israel Englander | 9K | $863.1K | -83% |
13F holdings as of Jun 30, 2026
Explore all tracked funds →What are LMAT's key statistics?
Key statistics as of Nov 5, 2026
How does LMAT's valuation compare with the Healthcare sector?
| Metric | LMAT | Healthcare median | Companies in median |
|---|---|---|---|
| P/E ratio | 28.1 | 28.8 | 113 |
| Net margin | 25.02% | 3.66% | 170 |
| Return on equity | 16.42% | 3.71% | 194 |
| Dividend yield (payers) | 1.05% | 1.59% | 55 |
Medians over the Healthcare stocks whose key statistics were refreshed in the last 35 days (newest Nov 9, 2026). P/E excludes loss-making companies.
LMAT price chart
Powered by TradingViewWhat does LEMAITRE VASCULAR INC do?
LeMaitre Vascular Inc. develops, manufactures, and markets specialized medical devices and implants designed for vascular surgery and the treatment of peripheral vascular disease. The company offers a comprehensive portfolio of products across six key categories: aortic, arteriovenous access, cardiac, carotid, lower extremity, and neuro applications. Its product lines include allografts—cryopreserved human tissue grafts used in vascular reconstruction—embolectomy catheters for removing blood clots from arteries, thrombectomy catheters for venous thrombi removal, and various synthetic and biologic grafts and patches. LeMaitre also provides human tissue cryopreservation services. The company distributes its products globally through direct sales to hospitals in over 25 countries and through distributors in more than 70 countries across North America, Europe, and Asia-Pacific. Founded in 1986 and headquartered in Burlington, Massachusetts, LeMaitre serves vascular surgeons performing both open surgical procedures and minimally invasive interventions, with the majority of its revenue generated from the United States market.